Blue Skies Space to build satellite fleet around the moon to map the ancient universe
The Italian Space Agency has picked European company Blue Skies Space to build a fleet of satellites around the moon to map the ancient universe.
Blue Skies has partnered with another space company, OHB Italia, to build the satellite fleet, called RadioLuna, which aims to see if small satellites around the moon can pick up faint FM radio signals from the early universe's so-called "Dark Ages," before the first stars were formed, OHB said in a statement
These radio signals are hard to detect on Earth; there's too much human-made radio interference. The idea is that, on the far side of the moon, the airwaves should be quiet enough to pick up the fainter cosmic radio signals. If the satellites can detect the signals, researchers can use them to map the universe's early days.
"We are grateful to the Italian Space Agency for funding this activity with our project partner OHB Italia to explore novel ways of delivering exciting science," Blue Skies co-founder and CEO Marcell Tessenyi said in a separate statement. A cost estimate and launch year for RadioLuna were not immediately available.
Tessenyi said the RadioLuna project stemmed from the global drive to create an economy on the moon. "Programs by space agencies such as ESA Moonlight or NASA Artemis can provide the transport, communication and timing infrastructure to projects such as RadioLuna," Tessenyi added.
The RadioLuna satellite network will use small cubesats equipped with commercial off-the-shelf components. The goal is to make the satellites simple and cost-effective.
"RadioLuna is a challenge where scientific ambition meets engineering pragmatism," Roberto Aceti, OHB Italia managing director, said in the statement. "We are proud to contribute to the development of an observatory that could open new frontiers in our understanding of the early universe."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
How Trump 2.0 is galvanizing European AI and defense tech
Trump's second term has helped fuel European spending for AI, defense, and climate startups. VCs and founders told Business Insider that Europe is now embracing so-called tech sovereignty. European startups like Mistral are focusing on developing their own AI infrastructure. "Make Europe's tech ecosystem great again" might not fit on a Trump campaign badge, but it's something he might unintentionally be delivering on. At least, that's what investors and founders on the continent are betting on as the US has become more protectionist with its economic policies and a less reliable ally for Ukraine. It's spurred investors in Europe to put more capital into defense startups, and tech companies and politicians to embrace so-called tech sovereignty in areas like AI and climate. "There's been a shift in deployment targets," Flavia Levi, a deep tech VC at Europe-based Join Capital, told Business Insider. "Now, we're talking about how money should be going into strengthening the critical technologies of Europe." European founders and investors also sense an opportunity. Six months into his second term, Donald Trump's sweeping tariffs and his "Big Beautiful Bill" have unsettled the US tech sector. They have slashed funding for clean energy projects, inflated manufacturing costs for hardware startups, and complicated visa requirements for global talent entering the country. Investors are backing Europe's defense startups Globally, defense tech has been a top focus for investors in 2025 — but especially so in Europe. Last year, defense startups on the continent raised a banner $2.4 billion, per PitchBook data. This year, they've already clinched $2.11 billion — with notable raises coming from the likes of Helsing and Quantum-Systems. The Trump administration's unpredictable relationships with Ukraine and NATO have been "a further wake-up call for the European continent to seek military and economic independence," said Alexander Lange, general partner at VC fund Inflection. He added that it's galvanizing a whole generation of founders to pursue "meaningful challenges in energy, compute infrastructure, manufacturing, and defense." Russia's attack on Ukraine in 2022 reminded Europe that war is a tangible reality on the continent, Matthew Wright, UK lead at defense tech startup Delian, told Business Insider. "Trump accelerated a lot of the thinking that was in place already," Wright said. "It encouraged European governments to spend more on defense so they don't have to rely on the US or third parties." Trump's bashing of ESG policies may have also indirectly influenced investors' approaches to European defense tech startups. "Historically, there has not been a lot of money in defense tech, because a lot of VCs and sometimes LPs have clauses whereby they agree not to invest in defense," said Levi. Limited partners, which provide capital for VCs, have historically gravitated to companies that "tick off ESG boxes," instead of building weapons — but this has started to change, she added. "LPs have started to change their investment thesis, and they're removing these clauses so VC funds have more freedom to invest in defense-related technologies," she said. VCs are championing European tech sovereignty Defense isn't the only sector getting extra investor attention in the Trump 2.0 era. This year, European government leaders such as France's Emmanuel Macron and the UK's Keir Starmer have committed billions in funding toward national AI ventures, often around "AI sovereignty" — the idea that a country or region should have control over the governance of its AI technologies and infrastructure. At London Tech Week in June, Arthur Mensch, the cofounder and CEO of OpenAI rival Mistral, said that trade tensions between the US and Europe had "accelerated conversations" about Europe becoming less dependent on US tech infrastructure. That same week, the Paris-based startup announced a partnership with Nvidia to establish sovereign computing infrastructure in France. Europe has also been stepping up in response to Stargate, the US's $500 billion AI infrastructure project announced in January, Roxanne Varza, director of startup incubator Station F, previously told Business Insider. At the February AI Summit in Paris — weeks after Trump announced Stargate in the White House — key corporations, VCs, and founders pledged to invest up to $150 billion in capital into Europe's AI ecosystem over the next five years. It's a significant amount of capital for Europe, whose startups have long lagged behind their US counterparts when securing VC funding. Critics attribute this gap to the continent's stringent regulations and fragmented ecosystem. In 2024, startups on the continent raised $51 billion in VC funding — trailing the $190 billion secured by US startups the same year. Trump's industrial policy is also causing ripple effects for climate startups in the US. Many are eyeing Europe as a haven for climate tech innovation and government funding at a time when federal funding for clean energy programs is being slashed. In all, founders and VCs in Europe are banking on a "historic opportunity" to establish a more coherent identity and strategy in the global technology race, said Julien Codorniou, general partner at 20VC. "We must position ourselves as a refuge for anyone who believes in technology, science, progress, and meritocracy." Read the original article on Business Insider Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
3 Reasons to Buy XRP Before 2026
Key Points Twice already in 2025, XRP has given investors a taste of just how fast it can soar in value. The end of regulatory uncertainty, combined with anticipation of new spot ETFs, could send XRP much higher. Some analysts expect XRP to triple or quadruple in value, but you should approach these predictions with a healthy dose of skepticism. 10 stocks we like better than XRP › After a spectacular summer rally that saw its price climb to a new 52-week high, XRP (CRYPTO: XRP) is attracting new interest from investors looking for a cryptocurrency with ultra-high upside. XRP also went on a stunning 580% rally in late 2024 and early 2025, so it definitely has the type of rocket fuel needed to reach escape velocity. There are three good reasons to load up on XRP now, while it's still trading for just $3. Wait too much longer, and you may miss out on its upside. Here's why. 1. The end to regulatory uncertainty around Ripple (XRP) First and foremost, all of the legal and regulatory issues that have dogged XRP during the past five years now appear to be over. A long-standing legal case involving the Securities and Exchange Commission (SEC) and Ripple, the company that launched the XRP token, was settled in August, with both sides agreeing to withdraw all appeals. Although Ripple will still need to pay a $125 million fine to the SEC, the path is now paved for rapid growth. Broadly speaking, the pro-crypto policies of the Trump administration have been a huge boon for XRP. Anticipation of these policies is what led to its spectacular post-election rally. Investors realized that the SEC would soon be taking a new approach to crypto, including a potential resolution of the Ripple case. 2. The imminent arrival of new spot ETFs With these regulatory and legal issues out of the way, the arrival of new spot exchange-traded funds (ETFs) for XRP could be any day now. A handful of top investment firms have already filed ETF applications with the SEC, and the growing expectation now is that final approval will come by mid-October. According to Bloomberg, the chances of approval are 95% by the end of 2025. So it's really a matter of when, not if, the spot XRP ETFs arrive this year. The conventional wisdom is that, as soon as the new ETFs start trading, the crypto will see a bounce in price. The same phenomenon occurred last year, when the new spot Bitcoin ETFs started trading. Investor money poured into the funds, sending the token's price soaring. 3. The growth prospects for XRP are off the charts The big question is just how much higher XRP can go from here. Its investor community is buzzing about recent predictions from European analysts suggesting that the world's third-largest cryptocurrency might be in for another spectacular rally. XRP could soar from $3 to $8, and perhaps even $13, if everything goes its way. Long term, it could hit $50 or even $100. For that to happen, a lot has to go right for XRP. According to the ultra-bullish scenario, XRP would eventually need to overtake Bitcoin in overall functionality. The idea here is that while Bitcoin is just a digital currency and store of value, XRP is a crypto token powering the Ripple payment network. So it could make possible blockchain-powered technological innovations, such as the tokenization of real-world assets. The problem, from my perspective, is that these grandiose claims about XRP have been made for years. And yet, in an entire decade, it has never once traded higher than $4. So it seems unreasonable to be talking about the crypto tripling, quadrupling, or quintupling in value anytime soon. Let's eclipse the old all-time high of $3.84 first, and then we can talk about soaring to the stratosphere. However, a strong case can be made that now is the time to buy XRP. The regulatory shackles have been taken off, and it has the real potential to move significantly higher. Just beware of any pie-in-the-sky forecasts that are grounded in nothing more than hope and a giant dollop of crypto optimism. Should you invest $1,000 in XRP right now? Before you buy stock in XRP, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and XRP wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Dominic Basulto has positions in Bitcoin and XRP. The Motley Fool has positions in and recommends Bitcoin and XRP. The Motley Fool has a disclosure policy. 3 Reasons to Buy XRP Before 2026 was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Using AI Made Doctors Worse at Spotting Cancer Without Assistance
Credit - Getty Images Health practitioners, companies, and others have for years hailed the potential benefits of AI in medicine, from improving medical imaging to outperforming doctors at diagnostic assessments. The transformative technology has even been predicted by AI enthusiasts to one day help find a 'cure to cancer.' But a new study has found that doctors who regularly used AI actually became less skilled within months. The study, which was published on Wednesday in the Lancet Gastroenterology and Hepatology journal, found that over the course of six months, clinicians became over-reliant on AI recommendations and became themselves 'less motivated, less focused, and less responsible when making cognitive decisions without AI assistance.' It's the latest study to demonstrate potential adverse outcomes on AI users. An earlier study by the Massachusetts Institute of Technology found that ChatGPT eroded critical thinking skills. How the study was conducted Researchers across various European institutions conducted an observational study surveying four endoscopy centers in Poland that participated in the Artificial Intelligence in Colonoscopy for Cancer Prevention (ACCEPT) trial. The study was funded by the European Commission and Japan Society for the Promotion of Science. As part of the trial, the centers had introduced AI tools for the detection of polyps—growths that can be benign or cancerous—in late 2021. The study looked at 1,443 non-AI-assisted colonoscopies out of a total 2,177 colonoscopies conducted between September 2021 and March 2022. The colonoscopies were performed by 19 experienced endoscopists. Researchers compared the quality of colonoscopy conducted three months before and three months after AI was implemented. Colonoscopies were conducted either with or without AI assistance, at random. Of those conducted without AI assistance, 795 were conducted before regular AI use was implemented and 648 were conducted after the AI tools were introduced. What the study found Three months before AI was introduced, the adenoma detection rate (ADR) was around 28%. Three months after AI was introduced, the rate dropped to 22% when clinicians were unassisted by AI. ADR is a commonly used quality indicator for colonoscopies and represents 'the proportion of screening colonoscopies performed by a physician that detect at least one histologically confirmed colorectal adenoma or adenocarcinoma.' Adenomas are precancerous growths, and a higher ADR is associated with a lower risk of colorectal cancer. The study found that AI did help endoscopists with detection when used, but once the assistance was removed, clinicians were worse at detection. Researchers attributed it to 'the natural human tendency to over-rely' on the recommendations of decision support systems like AI. 'Imagine that you want to travel anywhere, and you're unable to use Google Maps,' Marcin Romańczyk, co-author of the study and an assistant professor at the Medical University of Silesia, told MedPage Today. 'We call it the Google Maps effect. We try to get somewhere, and it's impossible to use a regular map. It works very similarly.' Implications of the study Omer Ahmad, a consultant gastroenterologist at University College Hospital London who wrote an editorial alongside the study but was not involved in its research, tells TIME that it's likely that exposure to AI weakened doctors' visual search habits and alerting gaze patterns, which are critical for detecting polyps. 'In essence, dependence on AI detection could dull human pattern recognition,' Ahmad says. He adds that regular use of AI could also 'reduce diagnostic confidence' when AI assistance is withdrawn, or that the endoscopists' skill of manoeuvring the colonoscope could be reduced. In comments to the Science Media Center (SMC), Catherine Menon, principal lecturer at the University of Hertfordshire's Department of Computer Science, said: 'Although de-skilling resulting from AI use has been raised as a theoretical risk in previous studies, this study is the first to present real-world data that might potentially indicate de-skilling arising from the use of AI in diagnostic colonoscopies.' Menon raised concerns that overreliance on AI could leave health practitioners at risk to technological compromise. Other experts are more cautious about drawing conclusions from a single study. Venet Osmani, a professor of clinical AI and machine learning at Queen Mary University of London, noted to SMC that the total number of colonoscopies—including both AI-assisted and non-AI-assisted ones—increased over the course of the study. The increased workload, Osmani suggested, could have led to clinician fatigue and poorer detection rates. Allan Tucker, a professor of artificial intelligence at Brunel University of London, also noted that with AI assistance, clinician performance improved overall. Concerns about deskilling due to automation bias, added Tucker to SMC, 'is not unique to AI systems and is a risk with the introduction of any new technology.' 'The ethical question then is whether we trust AI over humans,' said Tucker. 'Often, we expect there to be a human overseeing all AI decision-making but if the human experts are putting less effort into their own decisions as a result of introducing AI systems this could be problematic.' 'This is not simply about monitoring technology,' says Ahmad. 'It's about navigating the complexities of a new human-AI clinical ecosystem.' Establishing safeguards is critical, he adds, suggesting that beyond this study, people may need to focus on 'preserving essential skills in a world where AI becomes ubiquitous.' Contact us at letters@
